Prevalence of hypercortisolism in difficult-to-control type 2 diabetes
Buse JB, Kahn SE, Aroda VR, et al.
Diabetes Care. 2025:dc242841.
Leggi
Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors combination therapy for adults with type 2 diabetes mellitus: a network meta-analysis
Osman AA, Tayeb BA, Metzendorf MI, et al.
Cochrane Database Syst Rev. 2025;4(4):CD015952.
Leggi
Blood pressure lowering efficacy of dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonists compared to glucagon-like peptide-1 (GLP-1) receptor agonists
Grenet G, Gougeon A, Salzwedel DM, et al.
Cochrane Database Syst Rev. 2025;4(4):CD016144.
Leggi
Gut microbiome research: revealing the pathological mechanisms and treatment strategies of type 2 diabetes
Fang X, Zhang Y, Huang X, et al.
Diabetes Obes Metab. Pub. online 15 Apr 2025.
Leggi
Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: a network meta-analysis
Zhong J, Cai Z, Zhu G, Zhang J
Diabetes Obes Metab. Pub. online 10 Apr 2025.
Leggi
Timing of eating and glycemic control during pregnancy: a systematic review
Boege HL, Park C, Gagnier R, et al.
Nutr Metab Cardiovasc Dis. Pub. online 16 Apr 2025.
Leggi
Trends in utilization of glucose- and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study
Ostrominski JW, Ortega-Montiel J, Tesfaye H, et al.
Ann Intern Med. Pub. online 15 Apr 2025.
Leggi
OGGI ALLE ORE 15.00 – WEBINAR “I NUOVI ANNALI AMD”
Carissimi Soci, appuntamento oggi pomeriggio, alle ore 15.00, per la presentazione ufficiale dei nuovi Annali AMD 2024! Per iscriversi all’evento cliccare qui: https://dynamicomeducation.it/event/nuovi-annali-amd-2024 A seguire anche il programma scientifico del webinar Vi aspettiamo in diretta! La Segreteria Nazionale AMD
Leggi
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: a retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
Dunn TJ, Zhu Y, Gronroos NN, et al.
Diabetes Res Clin Pract. 2025:112162.
Leggi